[Palliative treatment of metastatic breast cancer with diethyldioxystilbene diphosphate (Honvan)].
21 postmenopausal patients with skin or/and bone metastases of breast carcinoma received 100-120 mg daily diethyldioxystilbene diphosphate (Honvan) orally. 7 objective remissions were observed, 8 tumors remained unchanged, and 6 were progressive. In 3 cases, rapid tumor progression was suggestive of estrogenic stimulation. Side effects were the same as for other estrogens. Diethyldioxystilbene disphosphate is an active estrogenic compound in the treatment of breast carcinoma.
D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D013267:Stilbenes / Q000627:therapeutic use*
D013267:Stilbenes
Traitement palliatif du cancer du sein métastatique par le diphosphate de diéthyldioxystilbène (honvan)